A randomized trial of pembrolizumab with or without radiotherapy (50 Gy in 4 fractions or 45 Gy in 15 fractions for SBRT-ineligible lesions) in metastatic NSCLC patients did not identify a benefit to the addition of SBRT in all patients, though those with low PD-L1 expression did see improvement in outcomes (Welsh et al., 2020). Here, CD274 is linked to non-small cell lung carcinoma.